Edition:
United States

Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

39.50USD
20 Apr 2018
Change (% chg)

$0.10 (+0.25%)
Prev Close
$39.40
Open
$39.10
Day's High
$40.05
Day's Low
$38.95
Volume
94,980
Avg. Vol
262,320
52-wk High
$49.90
52-wk Low
$11.80

Chart for

About

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or... (more)

Overall

Beta: 2.54
Market Cap(Mil.): $1,702.91
Shares Outstanding(Mil.): 43.11
Dividend: --
Yield (%): --

Financials

  ATRA.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -3.99 -- --
ROI: -53.78 -0.74 13.19
ROE: -55.37 -2.80 15.00

BRIEF-Atara Biotherapeutics prices public offering of stock at $35 per share​

* ATARA BIOTHERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Feb 28 2018

BRIEF-Atara Biotherapeutics Files For Potential Mixed Shelf Offering

* ATARA BIOTHERAPEUTICS INC FILES FOR A POTENTIAL MIXED SHELF OFFERING; SIZE UNDISCLOSED - SEC FILING ‍​ Source text (http://bit.ly/2CKPbcB) Further company coverage:

Feb 27 2018

BRIEF-Atara Says Commenced Underwritten Public Offering Of $150 Mln Shares Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

Feb 27 2018

BRIEF-Atara Biotherapeutics Posts Q4 Loss Of $1.15 Per Share

* ATARA BIOTHERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL PROGRESS

Feb 27 2018

BRIEF-Atara Biotherapeutics Says CFO Intends To Retire In April 2018

* ATARA BIOTHERAPEUTICS ANNOUNCES CHIEF FINANCIAL OFFICER INTENTION TO RETIRE IN APRIL 2018

Feb 21 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Proceed With Multiple Sclerosis study

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO PROCEED WITH ENROLLMENT AT U.S. SITES FOR ONGOING GLOBAL PHASE 1 CLINICAL STUDY TO EVALUATE ATA188 IN PATIENTS WITH PROGRESSIVE OR RELAPSING-REMITTING MULTIPLE SCLEROSIS

Jan 10 2018

BRIEF-Camber Capital Management Reports 6.7 Pct Passive Stake In Atara Biotherapeutics

* CAMBER CAPITAL MANAGEMENT LLC REPORTS A 6.7 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS AS OF JANUARY 04 - SEC FILING Source text : ( http://bit.ly/2m1PfiG ) Further company coverage:

Jan 05 2018

BRIEF-Atara Biotherapeutics Announces Proposed Offering Of Common Stock

* ATARA BIOTHERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

Jan 02 2018

BRIEF-Atara Biotherapeutics Gets FDA Clearance To Initiate Two Phase 3 Clinical Studies To Evaluate Tabelecleucel

* ATARA BIOTHERAPEUTICS ANNOUNCES FDA CLEARANCE TO INITIATE TWO PHASE 3 CLINICAL STUDIES TO EVALUATE TABELECLEUCEL IN PATIENTS WITH RITUXIMAB-REFRACTORY EPSTEIN-BARR VIRUS ASSOCIATED POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (EBV+PTLD)

Dec 29 2017

BRIEF-Morgan Stanley Reports 5 Pct Passive Stake In Atara Biotherapeutics As Of Nov 27

* MORGAN STANLEY REPORTS 5.0 PERCENT PASSIVE STAKE IN ATARA BIOTHERAPEUTICS INC AS OF NOVEMBER 27 - SEC FILING Source text: (http://bit.ly/2jrEZiq) Further company coverage:

Dec 07 2017

Competitors

  Price Chg
Biogen Inc (BIIB.OQ) $263.02 -3.00
Bayer AG (BAYGn.DE) €99.00 -0.60
Bayer AG (BAYE.F) -- --
Teva Pharmaceutical Industries Limited (TEVA.TA) 6,265.00 -67.00
Merck KGaA (MRCG.DE) €82.02 +0.02
Sanofi SA (SASY.PA) €65.28 -0.32
Novartis AG (NOVN.S) CHF76.08 -1.20
Roche Holding Ltd. (ROG.S) CHF215.65 -0.85
Roche Holding Ltd. (RO.S) CHF220.00 -0.20

Earnings vs. Estimates